Navigation Links
CTI Issues Statement Regarding Tosedostat Clinical Trial
Date:6/24/2013

l rate of 51 percent. Subset analyses suggested the greatest benefit occurred in the difficult-to-treat patients with prior myelodysplastic syndrome (MDS) or those that had received prior hypomethylating therapy (HMA). Adverse events were mild, predictable and manageable.

About Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Approximately 14,590 new cases of AML were expected to be diagnosed in the United States in 2013.1 As of January 2008 an estimated 30,993 people were living with (or were in remission from) AML.2 Although AML can occur at any age, adults aged 60 years and older are more likely to develop the disease than younger people. AML is a cancer characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML may develop from the progression of other diseases such as myelodysplastic syndrome (MDS), a blood cancer that also affects the bone marrow leading to a decrease in circulating red blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells leading to infections and bleeding. AML progresses rapidly and is typically fatal within weeks or months if left untreated. Although a substantial proportion of younger individuals who develop AML can be cured, AML in the elderly typically responds poorly to standard therapy with few complete remissions.

About CTI
Cell Therapeutics, Inc. (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to si
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
3. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
4. Endeavor Power Corporation Issues Corrections on two of its earlier Press Releases dated January 9, 2013 and March 8, 2013
5. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
6. ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act
9. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
10. BD Issues 2012 Sustainability Report
11. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 Emerus Holdings, ... of emergent, inpatient and diagnostic care in partnership ... signed a definitive agreement to receive a strategic ... Carson), a leading health care investment firm. ... high-quality, patient-centric acute episodic and ambulatory clinical services ...
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. Daniel K. ... Michael C. Burgess , M.D., and Joe ... st Century Cures Act, bipartisan legislation in support ... the United States Senate. UT ... department chairs, center directors, and leading researchers – joined ...
(Date:9/1/2015)... 2015  Edwards Lifesciences Corporation (NYSE: EW ), ... and hemodynamic monitoring, is scheduled to present at the ... Regency Boston in Boston, Massachusetts ... A. Mussallem , Edwards Lifesciences, chief executive officer, is ... company discussion with conference attendees at 10:10 a.m. PDT ...
Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
(Date:9/1/2015)... , ... September 01, 2015 , ... ... delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced ... , Based in San Francisco, Doctor On Demand provides immediate access to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Vending Machine,” is still strongly maintaining her firm’s success in the hair care ... In her upcoming city-to-city tour, Ellis will be providing “Look and learn” live ...
(Date:9/1/2015)... , ... September 01, 2015 ... ... Background Screeners (NAPBS®) has announced that Edge Information Management has been ... the Background Screening Credentialing Council (BSCC). , “Achieving and maintaining this ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, Inmar ... inception more than 35 years ago. A pilot program begun by the company in ... not just those intent on pursuing careers in these fields. The program is now ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Royal River ... new study that followed men and women for 19 years and found that, among ... did not take multivitamins. , The report is part of the September 2015 issue ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... UPMC Health Plan announced the,launch of a small ... small businesses -- UPMC Health Plan,s Small Business ... with 2 to 99,employees a high- quality, easy-to-implement ... tools, and a,dedicated account manager and customer service ...
... shows no link , THURSDAY, Oct. 18 (HealthDay News) -- ... or after exercise will not prevent muscle soreness, a new ... each involving from 10 to 30 people. , Nine of ... and the time spent stretching by participants varied from 40 ...
... and,Reported Diluted Earnings per Share Decreased 1% to $0.84. Diluted Earnings ... 2007 First Nine Months Worldwide Net Revenue Increased 10% to $16.6, ... Share, Before Certain Significant Items, Increased 10% ... to ...
... MITI ), a biopharmaceutical company focusing on ... treatment of cancer,inflammatory and autoimmune diseases, announced today ... Product Dossier (IMPD),for the conduct of a phase ... lymphoblastic leukemia (ALL) in Germany. MT103, a BiTE(R) ...
... 2,200-plus healthcare professionals and exhibitors registered for the,first-ever ... CHICAGO, Oct. 17 With studies from ... of students and,adults enrolling in distance education in ... Information and Management Systems Society (HIMSS),will host its ...
... Our ... Telemedicine Product Line, SUN VALLEY, Calif., Oct. 18 ... new,Bluetooth(R) enabled telemedicine products to their line of disease,management solutions for ... "The addition of A & D,s Bluetooth(R) enabled Blood Pressure ...
Cached Medicine News:Health News:UPMC Health Plan Launches New Product for Small Businesses 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 3Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 4Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 5Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 6Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 7Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 8Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 9Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 10Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 11Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 12Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 13Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 2Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 3Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 4Health News:XTend Medical (XDMC) Adds New Bluetooth(R) Telemedicine Products From A&D Medical 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: